(Q53947545)

22 May 2018

review article

1 reference

title

[Interferons and Behçet's disease]. (English)

1 reference

22 May 2018

0 references

B Wechsler

1

1 reference

22 May 2018

L T H Du-Boutin

series ordinal

2

1 reference

22 May 2018

language of work or name

French

0 references

publication date

1 November 2002

1 reference

22 May 2018

Revue de Médecine Interne

published in

1 reference

22 May 2018

volume

23 Suppl 4

1 reference

22 May 2018

page(s)

495s-499s

1 reference

22 May 2018

A controlled trial of azathioprine in Behçet's syndrome

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2802%2900665-3

7 January 2021

A double-blind trial of colchicine in Behçet's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2802%2900665-3

7 January 2021

Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2802%2900665-3

7 January 2021

Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2802%2900665-3

7 January 2021

Behçet's syndrome: treatment with recombinant leukocyte alpha-interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2802%2900665-3

7 January 2021

Beneficial effects of interferon-alpha 2b in Behçet's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2802%2900665-3

7 January 2021

Treatment of Adamantiades-Behçet disease with systemic interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2802%2900665-3

7 January 2021

Retraction: Interferon alfa-2b… in Behçet's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2802%2900665-3

7 January 2021

Treatment of ocular symptoms of Behçet's disease with interferon alpha 2a: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2802%2900665-3

7 January 2021

Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behçet's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2802%2900665-3

7 January 2021

Efficacy and safety of systemic recombinant interferon-alpha in Behçet's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2802%2900665-3

7 January 2021

Long-term effects of interferon alpha 2A treatment in Behçet's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2802%2900665-3

7 January 2021

Effects of interferon-alpha2a treatment on serum levels of tumor necrosis factor-alpha, tumor necrosis factor-alpha2 receptor, interleukin-2, interleukin-2 receptor, and E-selectin in Behçet's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2802%2900665-3

7 January 2021

Behçet's disease in patients with chronic myelogenous leukemia: possible role of interferon-alpha treatment in the occurrence of Behçet's symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2802%2900665-3

7 January 2021

Retinopathy associated with high-dose interferon alfa-2b therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2802%2900665-3

7 January 2021

Acute onset of ocular complications with interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2802%2900665-3

7 January 2021

Optic tract neuropathy complicating low-dose interferon treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2802%2900665-3

7 January 2021

Ocular complications with high-dose interferon alpha in chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2802%2900665-3

7 January 2021

Alpha-interferon-induced arthritis: clinical presentation treatment, and prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2802%2900665-3

7 January 2021

[Cutaneous reactions or necrosis from interferon alpha: can interferon be reintroduced after healing? Six case reports]

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2802%2900665-3

7 January 2021

10.1016/S0248-8663(02)00665-3

Identifiers

DOI

1 reference

22 May 2018

PubMed ID

12481405

1 reference

22 May 2018